Journals / Sakarya Tıp Dergisi / 2021 / Cilt: 11 - Sayı: 3

Evaluation of COVID-19 Patients Complaining of Balance Disorders with the Dizziness Handicap Inventory

Denge Bozukluğu Bulunan COVID-19 Hastalarının Baş Dönmesi Engellilik Envanteri ile Değerlendirilmesi

Pages
500–506
Publication Date
2021-09-22
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The inventory score means were higher in patients who were hospitalized and those with significant pathology on CT, and a statistically significant difference was also found (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Severe Acute Respiratory Syndrome-Coronovirus-2 (SARS-CoV-2), the Coronavirus Disease 2019 (COVID-19) agent, affects many systems in the body due to its rapidly developing nature and creates new findings every day.
📊
Key Findings & Data:Loss of balance has recently begun to be identified as a clinical manifestation of COVID-19.
💡
Conclusion & Impact:The inventory score means were higher in patients who were hospitalized and those with significant pathology on CT, and a statistically significant difference was also found (p
🔬Design:Survey & Empirical Study
📍Scope:2019 Verileri
⚙️Variables:COVID-19 · Dizziness · Baş Dönmesi

Abstract

Objective: Severe Acute Respiratory Syndrome-Coronovirus-2 (SARS-CoV-2), the Coronavirus Disease 2019 (COVID-19) agent, affects many systems in the body due to its rapidly developing nature and creates new findings every day. Loss of balance has recently begun to be identified as a clinical manifestation of COVID-19. In this study, the effects on the quality of life and the relationship between the degree of the disease were investigated by applying the “Dizziness Handicap Inventory” to patients who had COVID-19 and experienced balance problems during the active phase of the disease. Materials and Methods: Patients with COVID-19 were identified by being scanned digitally from the hospital registration system, and they were asked to participate in the survey by sending a "Google questionnaire" link. Patients who returned to the questionnaire and answered all questions were included in the study, and the data obtained were evaluated statistically. Results: Sixty four patients who answered all questions in the questionnaire were included in the study. Patients between the ages of 35-44 and 45-54 most frequently participated in the study. The mean for total inventory score was 35.90 ± 24.30 (min. 4-max. 88) in all patients. The inventory score means were higher in patients who were hospitalized and those with significant pathology on CT, and a statistically significant difference was also found (p

Özet

Amaç: Koronavirüs Hastalığı 2019 (COVID-19) ajanı olan Şiddetli Akut Solunum Sendromu-Koronovirüs-2 (SARS-CoV-2), hızla gelişen yapısı nedeniyle vücuttaki birçok sistemi etkilemekte ve her geçen gün yeni bulgular oluşturmaktadır. Denge kaybı, son zamanlarda COVID-19'un klinik bir belirtisi olarak tanımlanmaya başlandı. Bu çalışmada, hastalığın aktif döneminde COVID-19 olan ve denge sorunları yaşayan hastalara “Baş Dönmesi Engellilik Envanteri” uygulanarak yaşam kalitesi üzerine etkileri ve hastalığın derecesi arasındaki ilişki araştırılmıştır. Gereç ve Yöntemler: COVID-19 hastaları hastane kayıt sisteminden dijital olarak taranarak tespit edildi ve "Google anket" bağlantısı gönderilerek ankete katılmaları istendi. Ankete geri dönen ve tüm soruları cevaplayan hastalar çalışmaya dahil edildi ve elde edilen veriler istatistiksel olarak değerlendirildi. Bulgular: Anketteki tüm soruları yanıtlayan 64 hasta çalışmaya dahil edildi. Çalışmaya en sık 35-44 ve 45-54 yaşları arasındaki hastalar katıldı. Toplam envanter puanı ortalaması tüm hastalarda 35.90 ± 24.30 (min. 4-maks. 88) idi. Envanter skor ortalamaları, hastaneye yatırılan ve BT'de anlamlı patolojisi olanlarda daha yüksekti ve istatistiksel olarak anlamlı fark bulundu (p

🔖

Cite This Article

EĞİLMEZ, O. K., KORKMAZ, M. O., GÜVEN, M. (2021). Evaluation of COVID-19 Patients Complaining of Balance Disorders with the Dizziness Handicap Inventory. Sakarya Tıp Dergisi, Cilt: 11 - Sayı: 3, 500–506. https://ajindex.com/articles/398958

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Freni F, Meduri A, Gazia F, Nicastro V, Galletti C, Aragona P, et al. Symptomatology in head and neck district in coronavirus disease (COVID-19): A possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol 2020; 41: 102612. doi: 10.1016/j.amjoto.2020.102612
  2. World Health Organization.
  3. Johns Hopkins University and Medicine (2020) Coronavirus resource center. https://coronavirus.jhu.edu/. (Accessed 6 December 2020)
  4. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362: 263-70. doi: 10.1016/S0140-6736(03)13967-0
  5. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol 2020; 92: 552-5. doi: 10.1002/jmv.25728
  6. Wenting A, Gruters A, van Os Y, Verstraeten S, Valentijn S, Ponds R, et al. COVID-19 Neurological Manifestations and Underlying Mechanisms: A Scoping Review. Front Psychiatry 2020; 11: 860. doi: 10.3389/fpsyt.2020.00860
  7. Gautier JF, Ravussin Y. A New Symptom of COVID-19: Loss of Taste and Smell. Obesity (Silver Spring) 2020; 28: 848. doi: 10.1002/oby.22809
  8. Das G, Mukherjee N, Ghosh S. Neurological Insights of COVID-19 Pandemic. ACS Chem Neurosci 2020; 11: 1206-9. doi: 10.1021/acschemneuro.0c00201
  9. Asadi-Pooya AA, Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020; 413: 116832. doi: 10.1016/j.jns.2020.116832
  10. Liu K, Pan M, Xiao Z, Xu X. Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019-2020. J Neurol Neurosurg Psychiatry 2020; 91: 669-70. doi: 10.1136/jnnp-2020-323177
  11. Baig AM. Neurological manifestations in COVID-19 caused by SARS-CoV-2. CNS Neurosci Ther 2020; 26: 499-501. doi: 10.1111/cns.13372
  12. Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients. J Med Virol 2020: 10.1002/jmv.25903. doi: 10.1002/jmv.25903. Epub ahead of print
  13. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020; 70: 311-22. English, Spanish. doi: 10.33588/rn.7009.2020179
  14. Baig AM. Updates on What ACS Reported: Emerging Evidences of COVID-19 with Nervous System Involvement. ACS Chem Neurosci 2020; 11: 1204-5. doi: 10.1021/acschemneuro.0c